Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : SNYNF crawled date : 2022 - 09 - 15 save search
Positive Dupixent® (dupilumab) Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Published in The Lancet
Published: 2022-09-15 (Crawled : 23:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.74%
H: 0.91%
C: -0.74%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.52%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: 0.62%
H: 1.12%
C: 0.01%
dupixent children lancet dermatitis positive
New Jersey To Celebrate Year of Women in Manufacturing at 10th Annual 'MADE in New Jersey' Manufacturing Day
Published: 2022-09-15 (Crawled : 23:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.74%
H: 0.91%
C: -0.74%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.52%
H: 0.0%
C: 0.0%
day women year
Worldwide Irritable Bowel Syndrome with Constipation Drugs Industry to 2030 - by Drug Type, Prescription Type and Region
Published: 2022-09-15 (Crawled : 18:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -6.5%
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 0.97%
H: 0.0%
C: -3.99%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 0.22%
H: 0.14%
C: -0.43%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: 0.26%
H: 0.96%
C: -0.94%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.4%
H: 0.84%
C: 0.37%
IRWD | $7.94 4.47% 4.28% 2.5M
|
Health Technology
|
| O: 0.0%
H: 0.72%
C: -1.27%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.19%
H: 0.09%
C: -0.8%
ARDX | $6.5 0.93% 0.92% 5.6M
|
Health Technology
|
| O: -2.9%
H: 3.73%
C: 2.24%
drug
BioNJ Releases Speakers and Agenda for 2022 C-Suite Summit
Published: 2022-09-15 (Crawled : 17:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -6.5%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.4%
H: 0.84%
C: 0.37%
YOOBIC Celebrates Banner Year in North America With Accelerating Global Growth
Published: 2022-09-15 (Crawled : 14:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -6.5%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.4%
H: 0.84%
C: 0.37%
america global year growth
Experimental Test Promises to Predict Side-Effects and Cancer's Return in Patients Treated with Immunotherapy
Published: 2022-09-15 (Crawled : 14:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -6.5%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.4%
H: 0.84%
C: 0.37%
immunotherapy test cancer
Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics
Published: 2022-09-15 (Crawled : 13:20) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -6.5%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.4%
H: 0.84%
C: 0.37%
therapeutics
Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
Published: 2022-09-15 (Crawled : 13:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -6.5%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.4%
H: 0.84%
C: 0.37%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -0.41%
H: 3.27%
C: 1.6%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -0.9%
H: 2.16%
C: 1.01%
ongoing report nash study phase 1
Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
Published: 2022-09-15 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -6.5%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.4%
H: 0.84%
C: 0.37%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -0.41%
H: 3.27%
C: 1.6%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -0.9%
H: 2.16%
C: 1.01%
ongoing report nash study phase 1
Innate Pharma Reports First Half 2022 Financial Results and Business Update
Published: 2022-09-15 (Crawled : 06:00) - biospace.com/
BNPQF | $68.558 -13.4% 400
|
Finance
|
| O: -1.65%
H: 0.0%
C: -2.85%
BNPQY | $34.61 -2.68% 100K
|
Finance and Insurance
|
| O: -1.12%
H: 2.34%
C: 1.69%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -6.5%
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -0.88%
H: 0.45%
C: -0.87%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.4%
H: 0.84%
C: 0.37%
IPHA | $2.48 5.53% 5.24% 9.4K
|
Health Technology
|
| O: 3.25%
H: 0.0%
C: 0.0%
pharma financial update results
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.